SecBot SecBot
8-K ·Filed Aug 7, 2026

TMCI

TREACE MEDICAL CONCEPTS, INC.
MIXED
Impact 6/10
Horizonweeks Processed3mo ago SEC0001630627-26-000017
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The beat and guidance raise signal improving commercial traction from new products. Watch for H2 2026 revenue growth to turn positive as headwinds annualize; the stock may continue to re-rate if sequential improvement persists.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.76
T+0 close · Aug 7, 2026 · via day close
Latest settled
−6.93%
T+60 · $4.43
Vs SPY
−4.66%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 7 $4.76entry
  2. T+1 · 3mo ago −1.89%α −1.86% · $4.67
  3. T+5 · 3mo ago +0.63%α +0.23% · $4.79
  4. T+20 · 3mo ago +1.05%α +1.45% · $4.81
  5. T+60 · 16d ago −6.93%α −4.66% · $4.43
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Treace Medical Concepts reported Q2 2026 revenue of $45.4M (down 4% YoY but beating $43.9M consensus) and EPS of -$0.24 (beating -$0.30 consensus by 20%). The company raised full-year revenue guidance to $204M-$212M and improved Adjusted EBITDA loss guidance to $3M-$5M, while reducing year-to-date cash usage by 57%. New product adoption is accelerating, with 40% of Lapiplasty surgeons now using at least one of the three new bunion systems.

Key Financial Metrics

EPS
−$0.24
est −$0.30 · +20.0%
Revenue
$45.4M
est $43.9M · +3.4% · -4.2% YoY
Rating
strong beat
Guidance
$204M-$212M
raised
Free Cash Flow
-$2.7M
Gross Margin
78.5%

Key Facts

  • Q2 2026 revenue $45.4M vs $47.4M YoY (-4%), beating consensus of $43.9M
  • Q2 2026 GAAP EPS -$0.24 vs -$0.28 YoY, beating consensus of -$0.30
  • Full-year 2026 revenue guidance raised to $204M-$212M (from $202M-$212M)
  • Adjusted EBITDA loss guidance improved to $3.0M-$5.0M (from $4.0M-$6.0M)
  • Year-to-date cash usage reduced 57% vs prior year; cash + marketable securities $45.6M
  • Gross margin 78.5% vs 79.7% YoY; operating expenses down 8% YoY
  • 40% of Lapiplasty surgeons using ≥1 new bunion system (up from 35% in Q1 2026)
  • New product launches: SuperBite Compression Screw and HyperPlate XM systems

Financial Impact

Revenue beat of ~$1.5M (3.4%) and EPS beat of $0.06 (20%) vs consensus; guidance raise narrows the decline range

revenueepsadjusted EBITDAcash usage

Risk Factors

  • Revenue still declining YoY (-4%) and company remains unprofitable
  • Litigation costs ($2.1M in Q2) and restructuring charges ($0.8M) weigh on margins
  • Macroeconomic headwinds could dampen elective bunion surgery demand
  • Competition from minimally invasive bunion solutions may pressure market share

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
10% bullish (10 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001630627-26-000017
Document: tmci-20260807.htm0001630627-26-000017
Document: 0001630627-26-000017-index-headers.html0001630627-26-000017
Document: 0001630627-26-000017-index.html0001630627-26-000017
Document: 0001630627-26-000017.txt0001630627-26-000017
8-K Data (Synthetic)0001630627-26-000017

Track record

11 reports on TMCI

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +12.39% at T+60 after the Jul 13, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 16, 20261d ago SC 13G Neutral 4/10 Entry $4.42 to $4.44 Now $4.44 +0.45% ▲ +0.45% +1.47% vs SPY
  2. Nov 16, 20261d ago SC 13G/A Bearish 4/10 Entry $4.42 to $4.44 Now $4.44 −0.45% ▼ −0.45% −1.47% vs SPY
  3. Nov 12, 20266d ago Court Ruling Neutral 4/10 Entry $5.27 to $4.42 Now $4.44 −15.75% ▼ −16.13% −14.22% vs SPY
  4. Nov 6, 202611d ago 8-K Neutral 4/10 Entry $4.03 to $4.78 Now $4.44 +10.17% ▲ +18.61% +16.24% vs SPY
  5. Sep 17, 20268w ago Press Release Neutral 4/10 Entry $4.49 to $4.48 Now $4.44 −1.11% ▼ −0.22% −1.77% vs SPY
  6. Aug 7, 202614w ago 8-K Mixed 6/10 Viewing Entry $4.76 to $4.67 Now $4.44 −6.72% ▼ −1.89% −1.86% vs SPY
  7. Jul 13, 202618w ago Court Ruling Bearish 5/10 Entry $4.44 to $4.40 Now $4.44 −0.00% ▲ +0.90% +1.30% vs SPY
  8. May 8, 202627w ago Press Release Bearish 7/10 Entry $2.01 to $1.94 Now $4.44 −120.90% ▲ +3.48% +3.71% vs SPY
  9. Apr 24, 202629w ago Press Release Neutral 1/10 Entry $1.98 to $1.92 Now $4.44 +124.24% ▼ −3.03% −3.19% vs SPY
  10. Apr 9, 202631w ago 8-K Mixed 6/10 Entry $1.53 to $1.81 Now $4.44 +190.20% ▲ +18.30% +18.36% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens Thu (11h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 7, 2026